This site is intended for healthcare professionals
Diagnosis and management of primary hyperoxaluria type 1
Declaration of sponsorship Alnylam Pharmaceuticals


Declaration of sponsorship Alnylam Pharmaceuticals
Read time: 110 mins
Last updated:6th Apr 2021
Published:6th Apr 2021
Welcome to the primary hyperoxaluria type 1 (PH1) Learning Zone, which introduces the signs that raise suspicion of PH1 and discusses management options for this progressive, lethal disease.

PH1 is a life-limiting disease of oxalate overproduction that can affect adults and children and lead to recurrent urolithiasis, nephrocalcinosis and progressive renal decline, ultimately ending in end-stage kidney disease (ESKD) and death1.

Both symptoms and management approaches place a significant burden on patients and families, including hyperhydration, intensive dialysis and even liver/kidney transplantation1,2.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest